| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Protecting Your Limited Partnership |
|
Main Subject - Protecting Your Limited Partnership
The use of the Limited Partnership has grown in popularity over the last 25 years as both a way to limit liability and reduce exposure and risk as well as a tax and estate planning tool. Like any other business or investing tool, it can be used properly for its intended purpose or it can be misused, resulting in problems. PRACTICAL LESSONS LEARNED Though t According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product he Limited Partnership has been adopted in all states of the USA, not all limited partnership statutes are created equal. Some are much better than others, and some are worse. It’s important to be in compliance with state law requirements, remembering of course that some states have far more formality requirements than do others. Here are some useful suggestions.
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ke use of those jurisdictions where the limited partnership statute is not invasive of every partner’s privacy. Some states want each partner’s name and address, even if they are not the (managing) general partner. Other states are far more respectful of privacy and only require the contact information of the General Partner. lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. sdictions, this is normally just a statement of who the general partner is, along with their address. In others, it is more detailed and requires a financial report. here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe interests, investment trading accounts, mutual funds, etc. d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro entity filing providers (incorporators) who don’t know what they’re doing and they tend to provide a ‘generic’ agreement that is a gross disservice to their customers. The partnership agreement should be drafted by an attorney. AVOIDING IRS PROBLEMS A series of cases which culminated in 2005 (the Strangi cases) examined the misuse of Limited Partnerships, p ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc rticularly as to their misuse claiming deep tax discounts where the founder of the Partnership basically treated the assets of the Partnership as his own despite claiming to transfer them to the FLP. To avoid IRS problems, here are some ‘lessons learned’ to consider:
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ‘business purpose’. Doing so only asks for trouble. nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically personal financial accounts, not out of the Limited Partnership. The same goes for estate taxes. It might be prudent to have a life insurance policy sufficient to cover anticipated estate taxes. That should be held separate from your family’s Limited Partnership. and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ abusive by the IRS. In the Strangi case the IRS was very critical of Mr. Strangi’s occupying the home without paying rent after the home had been transferred to the Limited Partnership. The same would obviously be true for other ‘personal use’ items such as boats, art collections and vacation homes. ADMINISTERING THE LIMITED PARTNERSHIP One of the areas ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi where problems can arise is in the proper administration of the FLP. This includes not only the day-to-day operations, but also the funding of the Partnership. For example:
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a reement may list the asset on its initial list of partnership property. Changing title means more than just including an item on a list. Trading accounts at a brokerage for example might require that you close the previous existing account and open a new one, in the name of the Limited Partnership. dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod e-titled by means of a deed which conveys ownership and is recorded with the County Recorder where the property is located. cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin i>Avoid using assets belonging to the Limited Partnership for purposes other than those stated in the business purpose section of the Partnership Agreement. tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ntention of administering the Partnership in a fair and business-like manner. t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ts (i.e. their percentage of ownership). ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ts as to the Partnership Agreement. y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products nd investments. It should highlight any changes (positive or negative) and any upcoming business opportunities, as well to set forth a cash flow statement and balance sheet for every Partner to review. . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de elf to an attack by the IRS and would likely be successful. It is best to form a family’s Limited Partnership for a proper business purposes (i.e. managing investments, company stock, mutual funds, etc.) and to properly document the timely and proper administration of the Limited Partnership with accurate books and records. It is important to ‘walk the walk’ and not just ‘talk th elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip talk’. A Limited Partnership that is properly drafted, has a business purpose, is run in a business-like manner, and is established well before the death of the founder has a much better chance of withstanding any audit and proving to be an example of ‘how to do it right’. © Michael L. Potter – All Rights Reserved. This article may be reprinted with permission of the author tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Techno Gypsies - Freemasons Of The Third Millennia? Industrialisation And Education
|